Luspatercept combine with Deferasirox

PreclinicalSmall molecule

TThe First Affiliated Hospital of Zhejiang Chinese Medical University

Luspatercept combine with Deferasirox is one of 23 small molecule programs targeting Severe Aplastic Anemia. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Severe Aplastic AnemiaActive, not recruiting

Severe Aplastic AnemiaPreclinical

Active, not recruiting

Competition

Competitive Landscape

25 competitors in Severe Aplastic Anemia

#DrugCompanyPhaseTrials

Neoral

Novartis

Approved

13 2

Fludara

Sanofi

Phase 3

11 3

Promacta

GSK

Phase 3

6 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

16 5

Doptelet

Atgam

8 7

Cellcept

Roche

Phase 2

3 8

Rabbit ATG

Novartis

Phase 3

3 9

Nplate

Amgen

Phase 2

1 10

Rituxan

Roche

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q2 2027

N/ANot yet recruiting

Severe Aplastic Anemia

NCT06964971

Clinical

Trials by Indication[1]

Severe Aplastic Anemia1 trial

Treatment of Transfusion-dependent Nonsevere Aplastic Anemia With Luspatercept: a Multicenter Prospective Clinical Study

Not yet recruiting·TThe First Affiliated Hospital of Zhejiang Chinese Medical University·N/A·NCT06964971·90 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Luspatercept combine with Deferasirox. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Luspatercept combine with Deferasirox compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Luspatercept combine with Deferasirox. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — The First Affiliated Hospital of Zhejiang Chinese Medical University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: TThe First Affiliated Hospital of Zhejiang Chinese Medical University

Luspatercept combine with Deferasirox

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q2 2027

Trials by Indication[1]

Severe Aplastic Anemia1 trial

References

Drug Info

Quick Facts

Related News